Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug-Induced Cognitive Impairment.
Drug Saf
December 2024
Division of Neurology, Department of Clinical Sciences Lund, Lund University, Box 117, 22100, Lund, Sweden.
Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium.
View Article and Find Full Text PDFDrug-Induced Delirium Associated With Sacubitril/Valsartan in a Patient With Chronic Kidney Disease: A Case Report.
Cureus
October 2024
Internal Medicine, St Vincent Medical Center, Bridgeport, USA.
Article Synopsis
- Drug-induced neuropsychiatric symptoms, like delirium and hallucinations, are common, especially in patients with multiple health issues and taking many medications.
- Sacubitril/valsartan is a heart failure drug that helps reduce hospitalizations, particularly in patients with preserved ejection fraction (HFpEF).
- A case report details a 79-year-old male with HFpEF and end-stage kidney disease who experienced visual hallucinations after beginning treatment with sacubitril/valsartan.
Article Synopsis
- Drug-induced akathisia is a common but often overlooked extrapyramidal side effect of certain medications like antipsychotics and antidepressants.
- It's frequently misinterpreted as general restlessness or agitation due to the similarity of symptoms with various other conditions, making diagnosis challenging, especially outside of psychiatry and neurology.
- This condition can significantly impact a patient's quality of life and cause severe distress, yet it may worsen if treated incorrectly or with inappropriate medications.
Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993-2016.
Ann Gen Psychiatry
November 2024
Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany.
Background: Clinical practice suggests that older adults (i.e., ≥ 65 years of age) experience adverse drug reactions (ADRs) more often than younger patients (i.
View Article and Find Full Text PDFDisproportionality analysis of amenamevir-induced encephalopathy using the Japanese adverse drug event report database.
J Infect Chemother
January 2025
Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan; Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Article Synopsis
- The study investigates the relationship between amenamevir, a new anti-herpesvirus drug, and the risk of encephalopathy, a potential complication during herpes zoster treatment.
- Using data from the Japanese Adverse Drug Event Report (JADER) database, the researchers identified 246 patients treated with amenamevir and found a significant association between the drug and encephalopathy, with older age being a key risk factor.
- The findings highlight the need for healthcare providers to monitor elderly patients (especially those aged 70 and above) closely for signs of encephalopathy when prescribing amenamevir.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!